In the EU, GOHIBIC (vilobelimab) has been granted marketing authorization under exceptional circumstances for the treatment ...

The WisdomTree U.S. LargeCap Fund ETF offers earnings-based exposure, outperforming the S&P 500. Read why I reiterate my Buy ...

The University of Georgia's momentum on the recruiting trail continues to build, especially with five-star quarterback Jared Curtis already locked in for the class of 2026. Now, ...

CLEVELAND, May 19, 2025 (GLOBE NEWSWIRE) -- NovelMed is pleased to announce positive 12-week interim results from the ongoing ...

NovelMed announce positive 12-week interim results from phase II trial of Ruxoprubart in adult patients with PNH: Cleveland Wednesday, May 21, 2025, 12:00 Hrs [IST] NovelMed, a cl ...

The acquisition would significantly boost Novartis’ position in rare kidney disease IgA nephropathy (IgAN), which the Swiss big pharma is targeting with oral complement factor B inhibitor ...

The factor B inhibitor also allowed significantly more ... with regulators so we can bring this first-in-class alternative complement pathway inhibitor as the first oral monotherapy to people ...

A recent study reveals that weight-loss medications such as Ozempic may reduce the risk of obesity-related cancers, including ...

Discover the richest sources of vitamin B12 including shellfish, organ meats, dairy products, and fortified options that help ...